Cefiderocol

Cefiderocol, sold under the brand name Fetroja (by Shionogi) among others, is an <a href="/facts/Antibiotic/sF1kIfxg">antibiotic</a> used to treat complicated <a href="/facts/Urinary_tract_infections/4NwY9tL0">urinary tract infections</a> when no other options are available. It is indicated for the treatment of <a href="/facts/Antimicrobial_resistance/jsbAywgx">multi-drug-resistant</a> <a href="/facts/Gram-negative/S1PbVtp4">Gram-negative</a> <a href="/facts/Bacteria/wC8xSCsU">bacteria</a> including <a href="/facts/Pseudomonas_aeruginosa/HBhyIxAn">Pseudomonas aeruginosa</a>. It is given by <a href="/facts/Injection_into_a_vein/AwwuD3Nu">injection into a vein</a>.
Common side effects include diarrhea, infusion site reactions, constipation and rash.
Cefiderocol is in the <a href="/facts/Cephalosporin/WeB7I75T">cephalosporin</a> family of medications. It was approved for medical use in the United States in November 2019, and in the European Union in April 2020. In September 2020, cefiderocol (Fetroja) received FDA approval as supplemental New Drug Application (sNDA) for treatment of <a href="/facts/Hospital-acquired_pneumonia/nvhyPP9W">hospital-acquired bacterial pneumonia (HABP)</a> and <a href="/facts/Ventilator-associated_pneumonia/LvzHBPsE">ventilator-associated bacterial pneumonia (VABP)</a> when caused by Gram-negative bacteria resistant to other antibiotics. It is on the <a href="/facts/WHO_Model_List_of_Essential_Medicines/6kmu81Xm">World Health Organization's List of Essential Medicines</a>.

Cefiderocol open-in-new

Cefiderocol